In the training set, univariate analysis of clinical characteristics that might be associated with platinum-resistance in patients with epithelial ovarian cancer showed significant differences between platinum-sensitive and platinum-resistant patients in age, lymph node metastasis, vascular cancer thrombus, ascites cancer cells, neoadjuvant chemotherapy, and tumor marker HE4. This evidence concerns the gene WFDC2 and neoplasm.